On Thursday, Shares of Cardinal Health, Inc. (NYSE:CAH), dropped -5.13% to $84.34.
Cardinal Health, stated fiscal year 2015 third-quarter revenue of $25.4 billion and non-GAAP diluted earnings per share (EPS) from ongoing operations of $1.19. Non-GAAP operating earnings raised 17 percent to $657 million. On a GAAP basis, operating earnings raised 16 percent to $591 million, and diluted EPS from ongoing operations raised 20 percent to $1.09.
Revenue for the Pharmaceutical segment raised 20 percent to $22.6 billion due to growth from existing and new customers. Segment profit raised 25 percent to $567 million, driven by strong performance under the company’s generics program, which comprises the net benefit of Red Oak Sourcing in addition to the growth from existing and new customers.
Revenue for the Medical segment was up 4 percent to $2.8 billion, primarily due to contributions from acquisitions. Segment profit reduced 8 percent to $102 million as a result of reduced contribution from national brand distribution and the continued impact of market pressures in Canada.
Cardinal Health, Inc., a healthcare services company, provides pharmaceutical and medical products and services in the United States and internationally. The company operates in two segments, Pharmaceutical and Medical.
Shares of JA Solar Holdings Co., Ltd. (NASDAQ:JASO), declined -5.07% to $10.02, during its last trading session.
JA Solar, declared that it will hold its annual general meeting of shareholders (“AGM”) on Monday, June 1, 2015, at 10:30 a.m., Beijing Time, at its headquarters at No. 36, Jiang Chang San Road, Zhabei, Shanghai, the People’s Republic of China. The shareholder record date is May 5, 2015.
JA Solar Holdings Co., Ltd., through its auxiliaries, is engaged in the design, development, production, marketing, and sale of photovoltaic solar cells and solar power products based on crystalline silicon technologies.
At the end of Thursday’s trade, Shares of Rocket Fuel Inc. (NASDAQ:FUEL), dwindled -5.09% to $8.01, hitting its lowest level.
Local Corporation (LOCM), and Rocket Fuel, declared that they have signed a deal for Local’s new programmatic media-buying initiatives.
According to eMarketer, programmatic digital display advertising grew to $10 billion in 2014, up 137 percent from 2013. It is predictable to double to $20 billion in 2016.
Local Corporation also hopes to achieve higher performance for its programmatic initiatives by filtering and removing non-human traffic, using third-party tools and its own nTegrity™ solution.
Rocket Fuel Inc., a technology company, provides artificial-intelligence digital advertising solutions. The company’s artificial intelligence-driven technology platform is built on its real-time optimization engine, which leverages Big Data and its computational infrastructure to purchase and deliver highly-automated digital advertising campaigns.
Finally, Acorda Therapeutics, Inc. (NASDAQ:ACOR), ended its last trade with -5.05% loss, and closed at $30.07.
Acorda Therapeutics, declared its financial results for the first quarter ended March 31, 2015.
FINANCIAL RESULTS
The Company stated a GAAP net loss of $3.1 million for the quarter ended March 31, 2015, or $0.07 per diluted share. GAAP net income in the same quarter of 2014 was $0.7 million, or $0.02 per diluted share.
Non-GAAP net income for the quarter ended March 31, 2015 was $6.5 million, or $0.15 per diluted share. Non-GAAP net income in the same quarter of 2014 was $8.8 million, or $0.21 per diluted share. Non-GAAP net income excludes share based compensation charges, non-cash convertible debt, acquisition related expenses and tax adjustments.
For the quarter ended March 31, 2015, the Company stated AMPYRA net revenue of $92.4 million contrast to $72.5 million for the same quarter in 2014.
The Company is reiterating 2015 AMPYRA net sales guidance of $405-$420 million.
For the quarter ended March 31, 2015, the Company stated combined net revenue and royalties from ZANAFLEX and tizanidine of $2.6 million contrast to $3.1 million for the same quarter in 2014.
For the quarter ended March 31, 2015, the Company stated FAMPYRA royalties from sales outside of the U.S. of $2.3 million contrast to $2.4 million for the same quarter in 2014.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
